טוען...
Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer
Lung cancer is the leading cause of cancer death in men and women. Lung adenocarcinoma (LUAD), represents approximately 40% of all lung cancer cases. Advances in recent years, such as the identification of oncogenes and the use of immunotherapies, have changed the treatment of LUAD. Yet survival rat...
שמור ב:
| הוצא לאור ב: | Front Immunol |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6522855/ https://ncbi.nlm.nih.gov/pubmed/31134065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2019.00954 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|